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Abstract
Background: Data from the Iranian population for hypomania core symptom clusters are lacking. The aim of the
present study was therefore to apply the Farsi version of the Hypomania-Check-List 32 (HCL-32), and to explore its
factorial structure.
Methods: A total of 163 Iranian out-patients took part in the study; 61 suffered from Major Depressive Disorder
(MDD), and 102 suffered from Bipolar Disorders (BP). Participants completed the Mood Disorder Questionnaire
(MDQ) and the Hypomania Checklist (HCL-32). Exploratory factor analyses were used to examine the properties of
the HCL-32. A ROC-curve analysis was performed to calculate sensitivity and specificity.
Results: The HCL-32 differentiated between patients with MDD and with BP. Psychometric properties were
satisfactory: sensitivity: 73%; specificity: 91%. MDQ and HCL-32 did correlate highly. No differences were found
between patients suffering from BP I and BP II.
Discussion: Instead of the two-factorial structure of the HCL-32 reported previously, the present pattern of factorial
results suggest a distinction between four factors: two broadly positive dimensions of hypomania ("physically and
mentally active"; “positive social interactions”) and two rather negative dimensions ("risky behavior and substance
use"; “difficulties in social interaction and impatience”).
Conclusion: The Farsi version of the HCL-32 proved to be applicable, and therefore easy to introduce within a
clinical context. The pattern of results suggests a four factorial solution.
Background
There is evidence that bipolar disorders have been
under-diagnosed (cf. [1]), and recent findings suggest
that bipolar disorders are increasing among children
and adolescents [2]. However, increased efforts are
being made to overcome the lack of research and instru-
ments [3,4]. In this respect, the Hypomania Check-List
32 (HCL-32; [5]) has gained considerable importance.
For instance, the HCL-32 has been applied with adoles-
cents [6-8], with a non-clinical sample of young adults
[9], and with a broad range of patients suffering from
affective disorders in Europe, South America, and the
Far East [1,3]. In this respect, Carta et al [10] were able
to show in a clinical sample that the HCL-32 was
a sensitive screening instrument for bipolar disorder in
a psychiatric setting. Currently, a short version consist-
ing of 16 instead of 32 items is being validated [4], and
recently, the HCL-32 has been used to screen patients
suffering mood disorders more generally [11]. However,
for the Persian (or Farsi) language area, research is scare
and this holds particularly for the Islamic Republic of
Iran. In Iran, it is estimated that at least 7 million peo-
ple (9.43% of the population) suffer from one or more
psychiatric disorders [12], while the mental health pat-
tern in Iran is similar to that of western countries [12].
Bipolar disorders, however, are under-investigated in
this country. To address this lack of research, the aim of
the present study was four-fold: 1) to introduce a Farsi
version of the Hypomania-Check-List-32 (HCL-32; [5]),
a self-rating questionnaire to assess hypomania; 2) to
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between patients with Major Depressive Disorder
(MDD) and Bipolar Disorder (BP), and between patients
with BP I (periods of depressive and manic stages) and
BP II (periods of depressive and hypomanic stages) dis-
orders; 3) to compare the data with those from an
established questionnaire (Mood Disorder Question-
naire: MDQ; [13,14]), and 4) to explore the factorial
properties of the Farsi version.
Method
The study was conducted at the Iran University of
Medical Sciences, Tehran, and the Research Center for
Behavioural Disorders and Substance Abuse of Hama-
dan University of Medical Sciences, Hamadan. The
study was approved by the Hamadan ethical committee
(Iran). Written informed consent was obtained from
each participant before inclusion.
Patients
A total of 179 out-patients were approached. Patients
were included if they were willing and able to participate
and to complete the questionnaires, and if experts’ rat-
ings diagnosed MDD or BP according to the DSM-IV.
Of the patients approached, nine (5%) were excluded
due to comorbid disorders (substance abuse). 170 agreed
to participate at the first interview (95%), and 163 (91%)
completed the questionnaires correctly. Of these, 61 suf-
f e r e df r o mM a j o rD e p r e s s i v eD i s o r d e r( M D D )a n d1 0 2
suffered from Bipolar Disorder (BP I; n = 59 and BP II;
n = 43). Clinical characteristics of the patients are
shown in Table 1.
As shown in Table 1, the three groups did not differ
with respect to gender distribution, age or age at onset
of illness, but did differ with respect to the duration of
illness and the number of affective episodes.
Instruments
Experts at the two study centres diagnosed patients
based on DSM-IV criteria [15]. To do so, a psychiatric
interview was conducted using the SCID (Structured
Clinical Interview for DSM Disorders [16] and the Sche-
dule for Affective Disorders and Schizophrenia (SADS;
[17]). Afterwards, patients completed the Mood Disor-
ders Questionnaire (MDQ;[13], Farsi version: [14,18]).
The MDQ assesses bipolar disorders and consists of 13
items focusing on the occurrence of mood changes
(answers: yes (= 1) or no (= 0)), the occurrence of mood
disorders within the same period of time, and the possi-
ble adverse impact of mood changes on everyday life.
Psychometric properties of the Farsi version have been
shown to be robust and satisfactory [14,18]. Higher
scores reflect increased occurrence of bipolar disorders.
Cronbach’s alphas: entire sample:.85; patients with
MDD:.82; patients with BP I and II:.88.
Next, patients also completed the Hypomania-Check-
List 32 [5]. The HCL-32 consists of 32 statements con-
cerning behavior (e.g., “I spend more money/too much
money”), mood (e.g., “My mood is significantly better”),
and thoughts (e.g., “It h i n kf a s t e r ”) within the last four
weeks. Answers are “yes” (= 1) or “no” (= 0), and higher
scores reflect more marked hypomanic states. Cron-
bach’s alphas: entire sample:.84; patients with MDD:.82;
patients with BP I and II:.90. Cronbach’s alphas thus do
imply a high degree of internal consistency. To ensure
optimal translations, we rigorously followed the proce-
dure proposed by Brislin ([19]; cf. [1]); that is to say, the
English items were translated into Farsi, and then back-
translated into English by an independent translator.
Consensus was reached on a final version that was
subjected to the translation-retranslation process.
Overall, patients needed about 15 minutes to complete
the two questionnaires.
Table 1 Clinical characteristics of the sample
Samples Statistics
MDD BP I BP II
N 61 59 43
Male/female 25/36 35/24 24/19 X
2(2) = 4.17, p = .11
Mean age (SD) 35.60 (12.35) 35.12 (10.35) 36.00 (15.21) F(2, 160) = 0.06, p = .94
Clinical state during interview:
Recovery 34/61 (56%) 34/59 (58%) 21/43 (49%) X
2(2) = 0.83, p = .66
MDD 26/61 (43%) 23/59 (39%) 18/43 (42%) X
2(2) = 1.07, p = .59
Mania 0/61 (0%) 5/59 (8%) 0/43 (0%) X
2(2) = 9.10, p = .01
Hypomania 1/61 (2%) 3/59 (5%) 5/43 (12%) X
2(2) = 1.46, p = .48
Age at onset of illness (years: M (SD) 32.63 (10.92) 29.74 (8.89) 31.00 (11.09) F(2, 160) = 1.19, p = .31
Duration of illness (years: M (SD) 3.78 (3.99) 5.34 (4.23) 6.39 (6.14) F(2, 160) = 4.04, p = .02
Number of affective episodes 1.74 (0.87) 2.36 (1.24) 3.65 (1.60) F(2, 160) = 30.76, p = .00
MDD = Major Depressive Disorder; BP I = bipolar disorder I; PB II = bipolar disorder II; M = mean; SD = standard deviation.
Haghighi et al. BMC Psychiatry 2011, 11:14
http://www.biomedcentral.com/1471-244X/11/14
Page 2 of 6Statistical analyses
Pearson’s correlations were computed to compare the
sum scores between MDQ and HCL-32. To test for dif-
ferences between patients with MDD and BP with
respect to the MDQ and HCL-32, instead of the classi-
cal Student’s t-test the more robust Welch-test ‘’w’’ was
used [20,21]. Single Welch-tests were also used to com-
pare the present data with results from historical sam-
ples as reported in Angst et al. [1]. The HCL-32 items
were submitted to factor analysis with orthogonal rota-
tion. Logistic regression and ROC curve analysis were
performed to estimate the sensitivity and specificity of
HCL-32 as a screening method to discriminate between
patients with MDD and those with BP.
Test results with an alpha level below .05 were
reported as significant. However, we placed more
emphasis on effect sizes (d)f o l l o w i n gC o h e n ’sa d v i c e
[22,23] that the importance of p-values should not be
overestimated. Effect sizes for t-a n dw-tests were calcu-
lated following Cohen [22], with 0.49 ≥ d ≥ 0.20 indicat-
ing small (i.e., negligible practical importance), 0.79 ≥ d
≥ 0.50 indicating medium (i.e., moderate practical
importance), and d ≥ 0.80 indicating large (i.e., crucial
practical importance) effect sizes.
Results
General results
The relation between HCL-32 and MDQ scores was sta-
tistically significant (entire sample: r =. 6 8 ,p < .01;
patients with MDD: r = .61, p < .01; patients with BP:
r = .72, p < .001).
Compared to patients with MDD, patients with BP had
both higher HCL-32 scores (MDD: M = 16.26, SD = 9.39;
BP: M = 19.83, SD = 5.50: w(111.97) = 2.62, p = .01,
d = 0.59), and higher MDQ scores (MDD: M = 7.77, SD =
3.29; BP: M = 9.80, SD = 3.95: w(144.23) = 1.79, p = .04,
d = 0.51). No differences were found for HCL-32
and MDQ scores between patients with BP I or BP II
(ws < 0.88, ps > .38).
Comparison of the HCL-32 scores of the Iranian sample
with data from samples of patients suffering from MDD
and BP from Northern Europe, South America and East
Asia
Statistical characteristics of Northern European, South
American and East Asian were taken from Angst et al.
(2010) [1]. Compared to samples from Northern Europe,
South America and East Asia, the Iranian patients with
MDD did not differ in HCL-32 scores. Compared to
samples from Northern Europe, South America and East
Asia, the patients with BP did have higher scores,
though effect sizes were small to medium, indicating
negligible to medium practical importance (see Table 2).
Sensitivity and specificity of the HCL-32 scores with
respect to the diagnoses
After binary logistic regression with MDD and BP as a
dependent variable and HCL-32 scores as an indepen-
dent variable, sensitivity, i.e., the number of subjects
correctly identified with MDD, was found to be 73%,
whereas specificity, i.e., the number of subjects correctly
identified with BP, was found to be 91%, corresponding
to an overall precision of 82%. The optimal cut-off point
was 14.5. Applying this cut-off, 81% of the patients with
BP were above the cut-off score (patients with MDD:
31% were above the score. For a cut-off score of 7 for
Table 2 Statistical comparison of the HCL-32 data between Iranian out-patients and patients suffering from major
depressive disorders (MDD) and bipolar disorder (PB) from other countries
Samples from other countries
Northern Europe South America East Asia
N 672 423 631
HCL-32 total score (M and SD) 17.10 (6.00) 16.45 (6.05) 15.50 (6.70)
Iranian sample
MDD (N = 61)
HCL-32 total score (M and SD) 17.26 (6.39) 17.26 (6.39) 17.26 (6.39)
t-tests (df = 60) t = 0.20; p = .84 t = 0.99; p = .32 t = 2.15; p = .04
1
Effect sizes d 0.025 0.085 0.268
1
BP (N = 102)
HCL-32 total score (M and SD) 19.83 (5.50) 19.83 (5.50) 19.83 (5.50)
t-tests (df = 101) t = 8.96; p = .000 t = 6.21; p = .000 t = 7.95; p = .000
Effect sizes d 0.47 0.58 0.71
Notes: HCL-32 = Hypomania Check-List 32. MDD = major depressive disorders; BP = bipolar disorders.
1 Note that even if the p-value suggests a significant mean
difference, the effect size of 0.268 indicates that the mean difference was small and of negligible practical importance.
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28%. Considering the AUC (area under the curve) value
of 0.81 of the ROC curve, this result was at the middle,
but still satisfactory, limit for heuristic approaches
(cf. [24]).
Reducing the 32 items to factors
The first ten factors extracted by the factor analysis had
eigenvalues greater than 1, together accounting for 68%
of the overall variance. However, following Brown [25],
a further item selection was performed as follows: items
were excluded if they loaded on more than one factor
(i.e., cross-loadings), or if they showed small loadings on
all factors (i.e., low communalities). On this basis ten
out of 32 items were excluded. A factor analysis of the
22 remaining items yielded four factors with eigenvalues
greater than 1, together accounting for 78% of the var-
iance. The first factor, labelled “Positively physically and
mentally active” had an eigenvalue of 4.29; for the sec-
ond factor, labelled “Positive social interactions”,t h e
eigenvalue was 3.49; for third factor, labelled “Risky
behavior and substance use”, the eigenvalue was 2.35;
for the fourth factor, labelled “Difficulties in social inter-
action and impatience” the eigenvalue was 1.56 (see
Table 3). The first two factors may be considered posi-
tive dimensions ("bright” or “sunny” side of hypomania),
the latter two factors may be considered negative
dimensions ("dark” side of hypomania).
Discussion
The main results of the present study are that the Farsi
version of the HCL-32 did correlate highly with an
existing self-rating questionnaire for bipolar disorders
(MDQ), that it discriminated between patients with
MDD and BP, that mean scores did not substantially
differ from those of samples drawn from other conti-
nents, and that contrary to previous findings, a four-
factorial, rather than a two-factorial solution emerged.
Strong correlations between the established Farsi ver-
sion of the MDQ and the present HCL-32 do suggest
that the Farsi version of the HCL-32 measures the same
psychological construct, hypomanic stages within bipolar
Table 3 Items of the HCL-32 and their allocation to four factors.
Factors
Favorable dimensions Unfavorable dimensions
Physically and
mentally active
Positive social
interactions
Risky behavior and
substance use
Difficulties in social interaction
and impatience
I am physically more active .675 .189 -.059 .094
I engage in lots of new things .636 .080 .180 -.083
I enjoy my work more .623 .122 -.053 -.161
I am more interested in sex/..have
increased sexual desire
.608 -.083 .137 .367
I am more confident .605 .374 -.065 .001
I have more ideas .526 .221 .322 -.067
I think faster .593 .114 .063 .272
I do things more quickly .500 .360 .025 -.208
I feel more energetic 498 .278. .111 .003
I talk more .155 .656 .089 .193
I am more sociable .211 .618 .032 -.233
I am less shy .003 .563 .320 .054
I want to meet or do actually meet
more people
.180 .559 -.037 .093
I tend to drive faster .065 .061 .661 -.006
I drink more coffee .025 .085 .617 -.135
I drink more alcohol .032 .107 .581 .137
I take more risks in my daily life .182 -.171 .560 .462
I smoke more cigarettes .009 .059 .499 .133
I can be exhausting or irritating for
others
.164 -.035 .059 .688
I get into more quarrels -.062 .158 .129 .627
I am more impatient/...get irritable
more easily
-.270 .028 -.070 .539
My thoughts jump from topic to topic -.078 .265 .072 .462
Note: Bold factor loadings refer to the corresponding factors.
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sistently high internal consistency. Therefore, the Farsi
version seems applicable for these disorders. Moreover,
one needs only few minutes to complete the HCL-32;
this implies that the present version is a quick and easy
self-assessment tool. In this regard, the present data do
also fit well within the broad range of findings which
suggest a cross-cultural and generalized presence of
bipolar disorders [1,3].
Whereas the present questionnaire enables discrimina-
tion of patients with MDD and patients with BP, it does
not allow a distinction between patients with BP I and
BP II. The underlying reasons remain unclear, though
one might speculate that in the current sample differ-
ences between patients with BP I and BP II were not
present at the time of the survey. Another reason may
be that the mood states, rather than being categorical
entities, may be better viewed within a continuum ran-
ging from one pole (depressive symptoms) to another
(manic stage; cf. [7,26]), and that within this continuum
BP I and BP II stages are barely detectable by self-rating.
In this view, it is also of note that previous research
with the HCL-32 has not consistently allowed a distinc-
tion between BP I and BP II [1,5,27] (but see also [3]).
In contrast to previous studies (cf. [28,1,11,6,7]), a
four-factor rather than a two-factor structure emerged.
However, Holtmann et al. [8], applying the HCL-32 with
a sample of adolescents (mean age: 17.1 years), found a
three-factor structure, with the first factor ‘’active-
elated’’ reflecting symptoms related to energy and activ-
ity. By contrast, the adult factor ‘’irritable-risk taking’’
was better reflected by two separate factors (’’disinhib-
ited/stimulation-seeking’’ and ‘’irritable-erratic’’). Impor-
tantly, these factors were associated with externalizing
problems. Also differing from earlier two-factorial solu-
tions, Rybakowski et al. [29] reported a three-factor
solution for a sample of patients suffering from treat-
ment-resistant depression. Factor 1 was related to ele-
vated mood and increased activity, factor 2 was related
to increased sexual activity, whereas factor 3 was related
to irritability. In brief, it seems that the factorial struc-
ture of the HCL-32 is not conclusively limited to two
factors, and that solutions may vary as a function of the
sample concerned.
Limitations
Despite the new findings, several issues warrant against
generalization, and these data should be interpreted
cautiously. First, the sample size is rather small and
issues related to gender were not taken into account.
However, we emphasized effect size calculations which
are not sensitive to sample sizes. Second, comorbid sub-
stance use or dependence is relatively common in bipo-
lar disorder, and to some degree also in depression.
However, respondents with comorbid substance use
were excluded from the sample. As a result, data may
be biased and not entirely representative. Third, recall
of hypomanic symptoms in the past as assessed by the
HCL-32 and MDQ might have been biased by current
clinical state. Fourth, results from comparisons with
s a m p l e st a k e nf r o mA n g s te ta l .[ 1 ]s h o u l db ei n t e r -
preted cautiously because of the uneven distribution of
patients suffering from MDD and BP. Fifth, only
patients willing and able to participate and to complete
the questionnaires were included in the study; therefore,
again, results may be biased. Sixth, the cross-sectional
design does not allow investigation of further implica-
tions related to the long-term development of the
a s s e s s e dm o o dc h a n g e s .S e v e n t h ,c o m p a r e dt oo t h e r
findings (e.g., [10]) the cut-off of 14.5 points to distin-
guish between patients suffering from MDD and BP
might be rather high, though this cut-off point is com-
parable to other studies (cf. [5-7,9]). Last, statistical
comparisons between the present data and statistical
information from other samples were not systematically
controlled for gender and age.
Conclusion
The Farsi version of the HCL-32 is easy to complete and
provides detailed information (on four dimensions)
about what a patient thinks about her/his hypomanic
stages. Therefore, the questionnaire is easily applicable
within the clinical context. Future research might focus
on the issue of the extent to which these four dimen-
sions predict long-term development of patients’ mood
changes. Moreover, the Farsi version of the HCL-32 is
also widely applicable, since about 150 million of people
throughout the world use Farsi as first or second
language.
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